购物车
- 全部删除
- 您的购物车当前为空
BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).
为众多的药物研发团队赋能,
让新药发现更简单!
BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 4,160 | 6-8周 | |
25 mg | ¥ 10,600 | 6-8周 | |
50 mg | ¥ 13,800 | 6-8周 | |
100 mg | ¥ 17,500 | 6-8周 | |
1 mL x 10 mM (in DMSO) | ¥ 4,570 | 6-8周 |
产品描述 | BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM). |
靶点活性 | ERG (human):1.52 μM |
体内活性 | BKI-1369 reduces the parasite burden and disease severity in the gnotobiotic pig model. BKI-1369 has been well characterized for potency, metabolism, stability, toxicity, pharmacokinetics, and is potent against C. parvum in infected mice and calves. |
分子量 | 417.51 |
分子式 | C23H27N7O |
CAS No. | 1951431-22-3 |
密度 | 1.38 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容